Billet B.
- Country
- Belgium
- Department
- Pijnkliniek
Research Overview
Data & Insights
Has run more than one trial at 0 of 6 partner sites.
Specializations
Inflammatory Bowel Disease
Billet Bart’s investigations target ulcerative colitis and Crohn’s disease, emphasizing remission induction, mucosal healing, and long‑term disease control.
- Biologic and small‑molecule therapeutics
- Endoscopic and histologic response metrics
- Post‑surgical recurrence prevention
These efforts aim to refine therapeutic algorithms for chronic intestinal inflammation.
Solid Tumor Oncology
The investigator engages in clinical studies of major solid tumors, including non‑small cell lung cancer, breast cancer, and colorectal cancer, focusing on targeted and immuno‑oncology approaches.
- EGFR‑mutated and KRAS‑mutated lung adenocarcinoma
- HER2‑positive and triple‑negative breast malignancies
- Metastatic colorectal carcinoma with MSI‑high status
His work supports the integration of molecular profiling into personalized cancer therapy.
Hematologic Oncology
Research led by Billet Bart addresses malignant hematologic conditions such as acute myeloid leukemia, chronic lymphocytic leukemia, and various lymphomas, with emphasis on novel agents and transplant strategies.
- Targeted inhibitors for AML with IDH1/2 mutations
- BTK inhibition in CLL and mantle‑cell lymphoma
- Cellular therapies and allogeneic stem‑cell transplantation
These studies aim to improve survival and quality of life for patients with blood cancers.
Cardiovascular & Metabolic Medicine
Billet Bart contributes to trials involving acute coronary syndrome, atrial fibrillation, and type 2 diabetes mellitus, focusing on risk reduction and organ protection.
- Anticoagulation strategies for stroke prevention
- Cardioprotective agents post‑myocardial infarction
- Metabolic interventions for diabetic cardiovascular risk
This portfolio supports integrated management of cardiovascular and metabolic disorders.
Pulmonary Fibrosis & Respiratory Disorders
In the respiratory arena, the investigator focuses on idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, and related severe lung conditions, evaluating antifibrotic and anti‑inflammatory therapies.
- Novel antifibrotic compounds for IPF
- Bronchodilator and anti‑exacerbation regimens for COPD
- Management of severe viral lung infections
These initiatives aim to slow disease progression and improve respiratory function.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.